Elevation Oncology, Inc. (ELEV) - Volume dana dhuwit perusahaan

Tandha merek Elevation Oncology Inc. (ELEV)

Elevation Oncology is independently developing its oncology portfolio while seeking to establish global partnerships for distribution. The asset remains independent of economic cycles, as demand for cancer therapy is stable. However, a high cash burn rate and the risk of clinical trial failures pose a threat to the business. Current cash reserves demonstrate liquidity, with the parameter value equal to 0.08.

Cadangan dhuwit perusahaan: Elevation Oncology, Inc. (ELEV) kanggo 04.07.2022 - 02.08.2025

Rincian metrik keuangan lan pasar Elevation Oncology Inc. (ELEV)

Analisis kabeh metrik perusahaan:ELEV Elevation Oncology
Sampel barang Elevation Oncology, Inc.

Developing targeted therapies for rare cancers requires colossal expenditures on clinical trials. This indicator captures the remaining liquid assets of Elevation Oncology (ELEV), reflecting the issuer's actual financial stability. Analyzing the burn rate allows for an assessment of the business's runway before the next funding round. A high level of reserves confirms reliability but may signal stagnation in operational processes. Carefully examine the cash position history to evaluate investment risks.

Karo sapa Elevation Oncology saingan

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|SLRX (Salarius Pharmaceuticals, Inc.) - Dhuwit awis lan setara dhuwit awis perusahaan|PPBT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan American Oncology Network Inc|BGNE (beigene.com) - Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan CKPT (Checkpoint Therapeutics)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan